Bosch, Anemoon T. https://orcid.org/0009-0002-5384-9975
Sander, Josemir W. https://orcid.org/0000-0001-6041-9661
Thijs, Roland D. https://orcid.org/0000-0003-1435-8970
Funding for this research was provided by:
Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie
Epilepsiefonds ((2023-04))
Article History
Accepted: 15 July 2024
First Online: 7 August 2024
Change Date: 23 March 2025
Change Type: Update
Change Details: The original article has been corrected. Reference 43 was incorrectly cited and it has been corrected. The references 65 and 66 should have been interchanged in the reference list.
Change Date: 22 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40263-025-01176-6
Declarations
:
: EpilepsieNL (2023-04) and the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, supported this work (for ATB and RDT). The funders were not involved in the study design, collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.
: A.T.B. has no disclosures. R.D.T. reports lecture and consultancy fees from Medtronic, UCB, Angelini Pharma, Theravarance, Zogenix, Novartis, LivAssured, and Arvelle, and grants from Medtronic and NewLife Wearables. J.W.S. or his department has received grants from Eisai, Angelini Pharma and UCB. He has received personal compensation for serving on the Advisory Boards or Speaker’s Bureau for UCB and Angelini Pharma.
: Data sharing is not applicable as no data were generated or analysed during the study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Study conception and design was performed by A.T.B. and R.D.T.; data collection was carried out by A.T.B.; analysis and interpretation of results was carried out by A.T.B., R.D.T., and J.W.S.; and draft manuscript preparation was performed by A.T.B. All authors reviewed the results and approved the final version of the manuscript.